Blake Schutter Theil Wealth Advisors LLC Acquires New Position in Eli Lilly and Company (NYSE:LLY)

Blake Schutter Theil Wealth Advisors LLC bought a new position in shares of Eli Lilly and Company (NYSE:LLY) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 515 shares of the company’s stock, valued at approximately $456,000.

Several other large investors have also added to or reduced their stakes in LLY. D.B. Root & Company LLC raised its position in shares of Eli Lilly and Company by 9.5% during the 3rd quarter. D.B. Root & Company LLC now owns 402 shares of the company’s stock valued at $356,000 after purchasing an additional 35 shares during the period. Centennial Wealth Advisory LLC purchased a new stake in Eli Lilly and Company in the 3rd quarter worth $267,000. Maia Wealth LLC raised its holdings in Eli Lilly and Company by 10.5% during the third quarter. Maia Wealth LLC now owns 2,415 shares of the company’s stock valued at $2,153,000 after acquiring an additional 229 shares during the period. Umpqua Bank lifted its position in shares of Eli Lilly and Company by 96.5% in the third quarter. Umpqua Bank now owns 1,505 shares of the company’s stock valued at $1,333,000 after acquiring an additional 739 shares in the last quarter. Finally, Harvest Portfolios Group Inc. boosted its stake in shares of Eli Lilly and Company by 30.5% in the third quarter. Harvest Portfolios Group Inc. now owns 86,305 shares of the company’s stock worth $76,461,000 after acquiring an additional 20,146 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Citigroup lifted their target price on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the company a “buy” rating in a research note on Friday, October 25th. Wells Fargo & Company boosted their target price on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a report on Friday, August 9th. Truist Financial raised their target price on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research note on Thursday, October 10th. Barclays decreased their price target on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a research note on Thursday, October 31st. Finally, JPMorgan Chase & Co. raised their price objective on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a research report on Friday, September 13th. Four research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $1,008.41.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $776.47 on Thursday. Eli Lilly and Company has a 12-month low of $561.65 and a 12-month high of $972.53. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. The firm has a 50-day moving average price of $901.75 and a 200-day moving average price of $867.32. The firm has a market capitalization of $737.11 billion, a PE ratio of 83.94, a price-to-earnings-growth ratio of 3.05 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by ($0.34). The firm had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The firm’s revenue for the quarter was up 20.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.10 EPS. As a group, equities research analysts forecast that Eli Lilly and Company will post 13.21 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 0.67%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 56.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.